Minn. Ends Claims Against Novo Nordisk After It Agrees To Cap Insulin Costs At $35
NEWARK, N.J. — Minnesota on March 31 moved to dismiss, with prejudice, all of its claims against Novo Nordisk Inc. after a drugmaker signed a settlement agreement, release and order and...To view the full article, register now.
Already a subscriber? Click here to view full article